Faculty Collaboration Database

Argatroban Versus Bivalirudin in the Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia. J Pharm Pract 2021 Aug;34(4):529-534

Date

10/28/2019

Pubmed ID

31645190

DOI

10.1177/0897190019882866

Scopus ID

2-s2.0-85074444502 (requires institutional sign-in at Scopus site)   8 Citations

Abstract

BACKGROUND: Argatroban and bivalirudin are direct thrombin inhibitors (DTIs) used for the treatment of heparin-induced thrombocytopenia (HIT). The purpose of this study was to determine whether either agent offered an advantage in efficacy and ability to remain within the targeted therapeutic anticoagulation range.

METHODS: This was a single-center, retrospective, observational cohort study at a large academic medical center. The primary efficacy outcome was time to therapeutic anticoagulation, defined as total number of hours to achieve 2 consecutive activated partial thromboplastin time (aPTT) values in goal range.

RESULTS: A total of 91 patients were included in the analysis. Average time to initial therapeutic anticoagulation was 4.71 hours and 9.8 hours for the argatroban and bivalirudin groups, respectively (P < .01).

CONCLUSIONS: Argatroban may be advantageous compared to bivalirudin in achieving initial therapeutic anticoagulation goals among patients with suspected or confirmed HIT.

Author List

Duewell BE, Briski MJ, Feih JT, Rinka JRG, Tawil JN

MESH terms used to index this publication - Major topics in bold

Anticoagulants
Arginine
Heparin
Hirudins
Humans
Peptide Fragments
Pipecolic Acids
Recombinant Proteins
Retrospective Studies
Sulfonamides
Thrombocytopenia
Treatment Outcome